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Recently, we described a chimeric, hemagglutinin of highly pathogenic avian inﬂuenza virus (HPAIV) H5
expressing Newcastle disease virus (NDV)-based vector vaccine (chNDVFHNPMV8H5) in which NDV enve-
lope glycoproteins were replaced by those of avian paramyxovirus-8 (APMV-8). This chimeric vaccine
induced solid protection against lethal HPAIV H5N1 even in chickens with maternal antibodies against
NDV (MDA+). However, due to the absence of the major NDV immunogens it failed to induce protection
against Newcastle disease (ND). Here, we report on protection of MDA+ chickens against HPAI H5N1 and
ND, by vaccination with chNDVFHNPMV8H5 either on day 1 or day seven after hatch, and subsequent
immunization with live attenuated NDV seven days later. Vaccination was well tolerated and three weeks
after immunization, challenge infections with highly pathogenic NDV as well as HPAIV H5N1 were car-
ried out. All animals remained healthy without exhibiting any clinical signs, whereas non-vaccinated ani-
mals showed morbidity and mortality. Therefore, vaccination with chNDVFHNPMV8H5 can be followed by
NDV vaccination to protect chickens from HPAIV as well as NDV, indicating that the antibody response
against chNDVFHNPMV8H5 does not interfere with live ND vaccination.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Newcastle disease (ND) and avian inﬂuenza (AI) are the most
important infectious diseases of poultry.
ND caused by Newcastle disease virus (NDV) [1,2] is a highly
contagious disease of chickens listed by the world organization
of animal health [3] and is responsible for high losses in poultry
holdings. Depending on the pathogenicity of the virus strain, mor-
tality can amount to 100% after infection with virulent (velogenic)
strains. In contrast, lentogenic strains used for vaccination do not
induce any clinical signs in adult chickens [4,5]. Highly pathogenic
avian inﬂuenza virus (HPAIV) [6] is the cause of a highly lethal, sys-
temic disease of poultry, with clinical signs similar to ND but with
a more pronounced per-acute course of disease [7]. Currently cir-
culating HPAIV H5N1 spread to 63 countries causing death of more
than 400 million domestic poultry either by disease itself or dis-
ease control measures, e.g. culling [8]. 650 human infections lead-ing to 386 fatalities have been conﬁrmed until 24th of January in
2014, indicating a mortality rate of 60%. [9].
Thus, effective vaccination strategies to control ND and HPAI
are important for the poultry industry and to protect human
health.
NDV-based vector vaccines expressing HPAIV antigens are able
to induce protection in chickens against HPAIV without the risk of
reassortment [10]. Although, protective efﬁcacy was high when
used in speciﬁc pathogen free (SPF) chickens in experimental set-
tings [10–13], their use in the ﬁeld was frequently hampered by
the presence of antibodies against NDV induced by prior vaccina-
tion with NDV vaccines. In young chickens, maternally-derived
antibodies (MDA) against NDV presented a major obstacle [14].
To overcome this problem, a novel NDV-based vector virus was
constructed in which F and HN were substituted by the homolo-
gous proteins of avian paramyxovirus 8 (APMV-8) [15]. However,
the substitution of the NDV surface proteins by those of APMV-8
drastically decreased the protection against NDV infection. To in-
duce protection against both, NDV and HPAIV infection, the vacci-
nation protocol had to be optimized.
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Cells and viruses
Quail muscle cells clone 9 (QM9) were used for immunoﬂuores-
cence studies, while Leghorn hepatocellular epithelial cells (LMH)
were used for virus titration of swabs. Chicken embryo ﬁbroblasts
(CEF) were prepared from 11-day-old SPF chicken embryos. Re-
combinant NDV (rNDVGu) and chimeric NDV (chNDVFHNPMV8H5)
have been described [15,16]. HPAIV A/duck/Vietnam/TG24-01/
05(H5N1), kindly provided by P. Song Lien (National Centre for
Veterinary Diagnosis, Dongda, Vietnam), and APMV-8 strain APMV
8/goose/Delaware/1053/76 were obtained from the National Refer-
ence Laboratories for Avian Inﬂuenza (T. Harder) and Newcastle
disease. NDV strain Herts33/56 was kindly provided by MSD Ani-
mal Health.
Western Blot analyses
CEF were lysed 24 h after infection. Lysates were separated by
sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS–PAGE) and transferred to nitrocellulose membranes. Immu-
nostaining and detection was done as described previously [15].
Preparation of monospeciﬁc anti-NP rabbit sera
The pET19b vector and Rosettagami Escherichia coli cells (both
Novagen, Darmstadt, Germany) were used for expression of the
C-terminal 81 amino acids of the nucleoprotein of APMV-8/Dela-
ware/1053/1976. A hexa-histidin- and an Avi-tag (used as a biotin
acceptor site) [17] were positioned in-frame and N-terminally of
the APMV-8 NPct fragment. DNA encoding the heptamerization do-
main of the human C4 binding protein (C4BP) [18,19] was inserted
between the tags and the APMV-8 sequence with SGS-linker se-
quences placed between C4BP and the virus-speciﬁc sequences.
Plasmid pBirCam (Avidity, Aurora, U.S.A) over-expressing the bac-
terial biotin ligase BirAwas co-transformed into E. coli strain Roset-
tagami to ensure co-translational mono-biotinylation of the
recombinant APMV protein fragments at their Avi-tag. Mono-bio-
tinylated NPct was puriﬁed from Rosettagami cultures induced
with IPTG, refolded in vitro, emulsiﬁed in Freund’s incomplete
adjuvant and used to immunize rabbits (legal permission for ani-
mal immunization granted under LALLF M-V/TSD/7221.3-2.5-
010/10).
Fluorescence staining and microscopic examination
For confocal microscopy, QM9 cells were seeded in 24-well
plates on glass coverslips and infected at a multiplicity of infection
(moi) of 5. After 1 h incubation on ice and 12 h incubation at 37 C
and 3% CO2, cells were ﬁxed with 3.7% formaldehyde in phosphate
buffered saline (PBS), permeabilized with 0.1% Triton in PBS, and
blocked with 5% BSA in PBS. Subsequently, cells were incubated
with primary antibodies (mab-FNDV, mab-HNNDV, mab-NPNDV
[20]) or sera (rabbit-FAPMV8, rabbit-HNAPMV8 [15], rabbit-NPAPMV8,
chicken-HISAPMV8, rabbit-HISNDV), followed by washes with 5% bo-
vine serum albumin (BSA) in PBS. Subsequently, species speciﬁc
secondary antibodies labeled with Alexa Fluor 568 (a-rabbit)
(Invitrogen) or Alexa Fluor 488 (a-mouse) (Invitrogen) were
added, and after three washing steps, cells were mounted in Mow-
iol (Roth, Karlsruhe, Germany). Images were collected on a Leica
SP5 confocal microscope (Leica Microsystems GmbH, Wetzlar, Ger-
many) using a 63 oil immersion objective with a numerical aper-
ture of 1.4. Fluorochromes were excited using a 488-nm laser and a
561-nm laser. For higher sensitivity, hybrid detectors were applied(HyD2, 488 nm; HyD4, 568 nm). Brightﬁeld images were collected
simultaneously with the ﬂuorescence images using the transmit-
ted light detector. Sequential z-sections of stained cells were ac-
quired for maximum projection. Images were processed using
ImageJ software and Adobe Photoshop CS5 (Adobe systems).Animal experiments
Vaccination and challenge experiments were carried out in the
BSL3 and BSL3+ experimental animal facilities of the Friedrich-
Loefﬂer-Institut. All animal experiments were conducted following
German animal welfare regulations (LALLF M-V/TSD/7221.3-1.1-
053/10) and are given in Table SI2. Brieﬂy, ten SPF chickens with-
out maternally derived NDV antibodies (MDA-), hatched at the
Friedrich-Loefﬂer-Institut, were vaccinated oculonasally at three
weeks of age with 1e + 06 TCID50/animal of chNDVFHNPMV8H5.
MDA+ chickens were derived from a ﬂock of SPF-white leghorn
chickens, which had been immunized with a commercially avail-
able inactivated NDV vaccine (Nobilis Newcavac, MSD Animal
Health). 10–11 MDA+ chickens each were immunized oculonasally
with 1e + 06 TCID50/animal either on day 1 after hatch with
chNDVFHNPMV8H5 and on day seven with rNDVGu (group A), or
on day seven with chNDVFHNPMV8H5 and on day 14 with rNDVGu
(group B). Four to six non-vaccinated control chickens were kept as
control animals for each group.
Oropharyngeal and cloacal swabs of MDA- chickens were taken
on two, four, six and 12 days post vaccination (dpv), whereas
MDA+ chickens were sampled by combined oropharyngeal and
cloacal swabs taken four dpv.
Three weeks after vaccination, MDA animals immunized with
chNDVFHNPMV8H5 and non-immunized control chickens were
challenged by infection with velogenic NDV strain Herts 33/56.
Furthermore, MDA+ chickens immunized with chNDVFHNPMV8H5
followed by ND vaccination seven days later as well as non-immu-
nized control chickens were infected with HPAIV A/duck/Vietnam/
TG24-01/05 (group AAIV and BAIV) or velogenic NDV strain Herts
33/56 (group ANDV and BNDV). Three weeks after the respective
immunization, animals were infected via the oculonasal route with
1e + 06 TCID50/animal. Clinical signs were evaluated over a period
of eight days and scored as described previously [15]. Combined
oropharyngeal and cloacal swabs were taken on two, four, six
and 10 days after challenge (dpch). Heparinised blood samples of
all animals were investigated before vaccination, before challenge
infection, and of all surviving birds at the end of the 14-day-obser-
vation period by testing for AIV-, NDV- and APMV-8 speciﬁc anti-
bodies using the hemagglutination inhibition (HI) assay.Serology
HI assay was performed according to standard (92/66/EEC).Detection of virus and viral genome
Swabs were titrated in triplicate. RNA was isolated, detected by
RT-qPCR and transformed to genome equivalents (GEQ) as de-
scribed previously [15].Statistical data analysis
Differences between groups were statistically tested by appro-
priate Wilcoxon-tests for paired or unpaired data, respectively.
Bonferroni correction was applied in case of multiple testing. The
global signiﬁcance level was 0.05. All calculations were performed
using R software [21], Version 2.13.0 (2011-04-13).
Fig. 1. Investigation of cross reactivity, (A) Western blot analyses. After Western blotting of uninfected (1), NDV (2) –, and APMV-8 (3) infected cell lysates, proteins were
visualized by immunostaining with HIS against APMV-8 (a) and NDV (b). After incubation with the respective primary antibody, binding of peroxidase-conjugated species-
speciﬁc secondary antibodies was detected by chemiluminescent substrate (Pierce). Identiﬁed proteins are indicated on the right, molecular weights of marker proteins
(PAGE Ruler™ Prestained Protein ladder (Fermentas)) are indicated on the left. B) Immunoﬂuorescence microscopy. Cross reactivity between APMV-8 and NDV proteins was
analyzed by indirect immunoﬂuorescence using antibodies or –sera for virus speciﬁc proteins. QM9 cells were infected with APMV-8 (top), chNDVFHNPMV8H5 (middle) or
NDV (bottom) at a moi of 5 and incubated for 12 h. After ﬁxation, cells were sequentially stained with primary a-NDV antibodies or sera followed by staining with a-APMV-8
sera. Antibody binding was visualized with Alexa Fluor 488-conjugated species-speciﬁc secondary antibodies (Invitrogen) (green) for a-NDV antibodies and Alexa Fluor
568-conjugated species-speciﬁc secondary antibodies (Invitrogen) (red) for a-APMV-8 antisera. Antibodies and –sera are given above. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Table 1
Shedding of infectious virus after vaccination (TCID50/ml).
Vaccine chNDVFHNPMV8H5 rNDVGu
Group A B A B
Chicken nr.
1 – – – 1.26e + 02
2 – – – 1.26e + 03
3 – – – 2.25e + 02
4 – – – –
5 – – 1.26e + 02 1.26e + 03
6 – – – 1.26e + 02
7 – – – –
8 – – – 1.26e + 03
9 – – – 1.26e + 03
10 – – – –
–, no CPE was detected (corresponds to 64e + 01).
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Fig. 2. Viral shedding after vaccination. Combined swabs from oropharynx and
cloaca of chickens were analyzed for the presence of NDV NP gene-speciﬁc vRNA by
RT-qPCR on day four after each vaccination. Chickens of group A were vaccinated
with chNDVFHNPMV8H5 on day one after hatch and with rNDVGu on day seven,
chickens of group B were vaccinated with chNDVFHNPMV8H5 on day seven after
hatch and with rNDVGu on day 14. The number of NDV-vRNA positive swabs of
each group is given below the box plots. Signiﬁcant differences (P < 0.05, Bonferroni
correction) between different groups at the same time point after hatch and
infection are indicated by ⁄.
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Fig. 3. Serology. Serum samples of HPAIV challenged MDA+ chickens collected on
day 21 after vaccination before challenge and serum samples collected on day 14
after challenge were tested for antibodies speciﬁc for AIV-H5 (a) or APMV8 (b) by HI
assay. Serum samples of NDV challenged MDA+ chickens collected on day 21 after
vaccination before challenge, and serum samples collected on day 14 after
challenge were tested for antibodies speciﬁc for NDV (c) or APMV8 (d) speciﬁc
antibodies by HI assay. Number of seropositive animals (HI titer > 2log2) is given
below the box plots. Signiﬁcant differences (P < 0.05) between two values are
marked by the same letter.
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Detection of cross reaction between NDV and APMV-8 proteins
APMV-8 speciﬁc proteins were detected by chicken-HISAPMV8,
while the same serum did not react with any NDV speciﬁc proteins
in Western blot analyses (Fig. 1A). In contrast, the rabbit-HISNDV
detected the expected NDV proteins, but reacted weakly also with
a 70 kDa protein of APMV-8 which could represent APMV-8 HN
protein, indicating a slight cross reaction of the anti-NDV hyperim-
mune serum with APMV-8 HN (Fig. 1A). In indirect immunoﬂuo-
rescence, no cross reaction between mab FNDV and HNNDV and
APMV-8 was detected (Fig. 1B column 1, 2). In contrast, the
NPAPMV8 serum detected NP of all investigated viruses, indicating
that in living cells cross reaction between NDV and APMV-8 can oc-
cur with antibodies against NP but not those directed against sur-
face glycoproteins F and HN (Fig. 1B).Protection of chNDVFHNPMV8H5 vaccinated MDA chickens against
velogenic NDV infection
The previously described recombinant vectored vaccine
chNDVFHNPMV8H5 provided excellent protection against a lethalHPAIV infection [15]. However, protection against velogenic NDV
Herts 33/56 failed. After immunization of three-week-old SPF
chickens with chNDVFHNPMV8H5 only one out of ten chickens sur-
vived a challenge infection with velogenic NDV Herts 33/56 three
weeks later, while all non-vaccinated control animals died (SI 1).Vaccination of MDA+ chickens with chNDVFHNPMV8H5 and rNDVGu
induces bivalent immune responses
NDV-antibody titers in sera taken on day 1 after hatch of MDA+
chickens were between 210 and 211, indicating a high level of MDA.
All chickens tolerated immunizations on day 1 or seven for
chNDVFHNPMV8H5 or day seven and 14 for NDV without exhibiting
any signs of disease during the three-weeks-observation period
after vaccination. Detection of infectious chNDVFHNPMV8H5 virus
in swabs obtained four dpv failed (Table 1). In contrast, all swabs
of group A and seven out of ten swabs of group B tested positive
by RT-qPCR, indicating low-level replication of the vaccine virus
(Fig. 2).
After NDV immunization on day seven, vaccine virus was re-
isolated from one of the 10 animals four dpv (group ANDV), whereas
virus was recovered from seven out of ten animals vaccinated on
day 14 and sampled four days later (group BNDV) (Table 1). This
coincides with the RT-qPCR results detecting vRNA in four (group
ANDV) and seven (group BNDV) out of ten vaccinated animals respec-
tively, indicating a higher level of rNDVGu replication in chickens
immunized on day 14 after hatch (Fig. 2).
Serum samples tested for speciﬁc antibodies by HI assay 21 dpv
revealed that the level of antibodies against APMV-8 and AIV H5
was indistinguishable between groups A and B. In contrast, the le-
vel of NDV speciﬁc antibodies was signiﬁcantly higher in the group
BNDV that received the rNDVGu vaccine on day 14 instead of day
seven (Fig. 3).
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induces bivalent protective immunity
Regardless of the time of immunization, all chNDVFHNPMV8H5-
immunized chickens survived a lethal HPAI H5 challenge infection
without exhibiting any clinical signs (Fig. 4A). In contrast, all birds
of both control groups died within two days, shedding high
amounts of virus (SI 3), conﬁrmed by RT-qPCR (Fig. 4A). From vac-G
EQ
/m
l
1e+2
1e+3
1e+4
1e+5
1e+6
1e+7
1e+8
1e+9
G
EQ
/m
l
1e+2
1e+3
1e+4
1e+5
1e+6
1e+7
1e+8
1e+9
ANDV
0.0
0 2 4 6 8
dead
sick
healthy
control (n=5)
vaccinated (n=10)
 BNDV(c)
0.325
0.0
   dpch
0.063
(d)
(a) (b)B
G
EQ
/m
l
1e+2
1e+3
1e+4
1e+5
1e+6
1e+7
1e+8
1e+9
dead
sick
healthy
control (n=4)
vaccinated (n=11)
G
EQ
/m
l
1e+2
1e+3
1e+4
1e+5
1e+6
1e+7
1e+8
1e+9
0 2 4 6 8
dead
sick
healthy
vaccinated (n=10)
control (n=4)
1.75
0.00
BAIV (d)(c)
dead
sick
healthy
vaccinated (n=10)
control (n=4)
AAIV
1.875
0.00
(b)(a)A
   dpch
NDVcinated chickens, AIV was re-isolated only in a single animal of
group A two days post challenge (dpch) (SI 3) and viral genome
was only detected by RT-qPCR in one out of ten chickens of both
groups on day two after challenge. Shedding ceased and could
not be detected in any subsequent samples.
NDV challenge infection, carried out three weeks after ND vac-
cination did not induce any mortality in MDA+ chickens, irrespec-
tive of the vaccination status. However, all animals of the controlANDVANDV control
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four out of ﬁve non-immunized animals of control group ANDV, and
BNDV, respectively, showed clinical signs (Fig. 4B). In contrast, none
of the vaccinated animals developed any clinical signs, although
infectious virus could be recovered from up to 50% of vaccinated
chickens by 6 dpch. Similar results were obtained by RT-qPCR
(Fig. 4B). Quantitative analysis indicated a higher virus replication
rate in MDA+ control birds, compared to the respective vaccinated
groups. Furthermore, replication of velogenic NDV was signiﬁ-
cantly higher in chickens of group BNDVcontrol, challenged 35 days
after hatch, than in chickens of group ANDVcontrol, challenged
28 days after hatch. Interestingly, viral shedding ended in all but
two chickens of control group BNDV on day six, regardless whether
tested by RT-qPCR or infectivity. Only from two non-vaccinated
MDA+ chickens which had been infected on day 35 post hatch,
virus was recovered up to day ten after challenge (Fig. 4B).
NDV speciﬁc antibody response was boosted by the NDV chal-
lenge infection as demonstrated by a signiﬁcant increase after
challenge for both groups reaching similar HI-titer 14 dpch (Fig. 3).Discussion
The vector vaccine chNDVFHNPMV8H5 successfully induced pro-
tection from HPAIV H5N1 challenge also in chickens with NDV-
speciﬁc MDA [15]. However, vaccination of chickens with this vec-
tor no longer induced protection against NDV (SI 1). Correspond-
ingly, prior chNDVFHNPMV8H5 vaccination of one-day-old or
seven-day-old NDV-MDA+ chickens did not prevent subsequent
replication of NDV vaccine strain rNDVGu. Shedding of rNDVGu
was detected in both groups by virus re-isolation as well as by
RT-qPCR on day four after vaccination. Consistent with a decline
of MDA in maturing chickens [22], virus detection rate was higher
in chickens of group B receiving the vaccine on day 14 post hatch
instead of day seven post hatch (group A) (Fig. 2). Corresponding
to the level of virus replication, antibody induction was lower in
group A than in group B and, conversely, the amount of virus shed
after challenge was higher in group A (Fig. 3, 4B). It is remarkable
that in both groups, NDV speciﬁc antibody levels were below the
MDA level, detected on day one post hatch but reached similar le-
vel after challenge infection.
Replication of chNDVFHNPMV8H5 was more efﬁcient than of
NDV vaccine (Fig. 2). However, in contrast to the NDV vaccine,
detection rate of chNDVFHNPMV8H5 in MDA+ animals that were
older when receiving the vaccine was decreased, indicating thatFig. 4. Clinical course and viral shedding, (A) after HPAIV H5N1 challenge infection. (a) M
and with rNDVGu on day seven after hatch, and naive controls were challenged on day 2
daily classiﬁed as healthy (0), sick (1), or dead (2) over a period of eight days. The averag
cloacal swabs of MDA+ chickens immunized with chNDVFHNPMV8H5 on day one (group A
infection. Analysis for presence of AIV NP gene-speciﬁc sequences was performed by R
Signiﬁcant differences (P < 0.0125, Bonferroni correction) between vaccinated groups an
with chNDVFHNPMV8H5 on day seven after hatch and with rNDVGu seven days later wer
on day 21 after chNDVFHNPMV8H5 vaccination and daily classiﬁed as healthy (0), sick (1
group are indicated. (d) Combined oropharyngeal and cloacal swabs of MDA+ chickens
animals were taken at indicated time points after challenge infection. Analysis for prese
positive swabs by RT-qPCR is given below the box plots. Signiﬁcant differences (P < 0.012
(B) After velogenic NDV challenge infection. (a) MDA+ chickens of group A which were v
hatch were challenged together with naive controls with velogenic NDV strain Herts33/5
dead (2) over a period of 8 days. The average scores of all animals of each group are indic
chickens and control animals were taken on indicated days. Immunization was performe
rNDVGu. Swabs were analyzed for the presence of NDV NP gene-speciﬁc vRNA by RT-
differences (P < 0.0125, Bonferroni correction) between different values are indicated
chNDVFHNPMV8H5 on day seven after hatch and with rNDVGu seven days later were chal
after rNDVGu vaccination and daily classiﬁed as healthy (0), sick (1), or dead (2) over a p
Combined oropharyngeal and cloacal swabs of MDA+ chickens of group B and control
presence of NDV NP gene-speciﬁc sequences was performed by RT-qPCR. Number of pos
Bonferroni correction) between different values are indicated by the same letter.
3not pre-existing MDA but rather onset of immune competence of
the host inﬂuenced virus replication. In this context it is interesting
to note that despite high levels of genomic RNA no infectious virus
was recovered.
Altogether, these in vivo results support the notion that cross
reactivity of surface glycoproteins of NDV and APMV-8 is absent
and that immune responses to internal proteins of NDV which
may include cell mediated immunity do not interfere with replica-
tion of our chimeric vaccine vector. A puzzling result in this con-
text is the increase of APMV-8 speciﬁc antibody responses in
both NDV-challenged groups (ANDV and BNDV) that is absent in
birds challenged with AIV, and apparently contradicts lack of cross
reactive epitopes on APMV-1 and APMV-8 HN-protein (Fig. 3).
However, for effector memory T-cells it is known that helper func-
tion for antibody production can be re-activated without speciﬁc
antigen re-stimulation, only by presence of cytokines [23]. In this
context, replication of virulent NDV Herts33/56 would induce lev-
els of cytokines sufﬁcient to trigger reactivation of APMV-8 HN
speciﬁc effector memory T-cells, whereas due to efﬁcient reduction
of HPAIV H5 replication such stimulus is missing. This ﬁnding is of
particular relevance in the light of possible serological DIVA strat-
egies and needs further investigation.
Subsequent NDV vaccination after immunization with
chNDVFHNPMV8H5 induced protection not only from HPAIV H5N1
but also from velogenic NDV which is of high practical relevance.
However, the clinical read out was severely inﬂuenced by the pres-
ence of MDA. NDV challenge of non-immunized SPF chickens in-
duced 100% mortality (SI 1b) which is a prerequisite to approve
efﬁcacy of ND vaccines, according to criteria of the OIE and Euro-
pean pharmacopoeia. In experiments with MDA+ chickens, only
some chickens of control groups had clinical signs after NDV chal-
lenge, resulting in a clinical index of only 0.063 and 0.325, respec-
tively. Therefore, to test efﬁcacy of the vaccine in MDA+ chickens,
we did not rely only on clinical score, but used viral shedding as an
additional parameter. We could demonstrate that both NDV vacci-
nated MDA+ groups did not only tolerate challenge with virulent
NDV without showing any clinical signs but had signiﬁcantly re-
duced levels of challenge virus shedding. Moreover, our ﬁndings
highlight the fact that chickens with maternally derived NDV anti-
bodies may withstand clinical disease but sustain NDV circulation
within a ﬂock.
However, the presence of antibodies against AIV H5 could pos-
sibly interfere with the replication and therefore affect protection
against HPAIV after vaccination with chNDVFHNPMV8H5. To coun-
teract this, described vaccination protocol has been tested thatDA+ chickens of group A which were vaccinated with chNDVFHNPMV8H5 on day one
1 after chNDVFHNPMV8H5 vaccination with A/duck/Vietnam/TG24-01/05(H5N1) and
e scores of all animals of each group are indicated. (b) Combined oropharyngeal and
) after hatch and control animals were taken at indicated time points after challenge
T-qPCR. The number of positive swabs by RT-qPCR is given below the box plots.
d controls are indicated by ⁄. (c) MDA+ chickens of group B which were vaccinated
e challenged together with naive controls with A/duck/Vietnam/TG24–01/05(H5N1)
), or dead (2) over a period of eight days. The average scores of all animals of each
immunized with chNDVFHNPMV8H5 on day seven (group B) after hatch and control
nce of AIV NP gene-speciﬁc sequences was performed by RT-qPCR. The number of
5, Bonferroni correction) between vaccinated groups and controls are indicated by ⁄.
accinated with chNDVFHNPMV8H5 on day one and with rNDVGu on day seven after
6 on day 21 after rNDVGu vaccination and daily classiﬁed as healthy (0), sick (1), or
ated. (b) Combined swab samples from oropharynx and cloaca of immunized MDA+
d on day one after hatch with chNDVFHNPMV8H5 and on day seven after hatch with
qPCR. Number of positive swabs by RT-qPCR is given below box plots. Signiﬁcant
by the same letter. (c) MDA+ chickens of group B which were vaccinated with
lenged together with naive controls with velogenic NDV strain Herts33/56 on day 21
eriod of eight days. The average scores of all animals of each group are indicated. (d)
animals were taken at indicated time points after challenge infection. Analysis of
itive swabs by RT-qPCR is given below box plots. Signiﬁcant differences (P < 0.0125,
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C. Steglich et al. / Trials in Vaccinology 3 (2014) 65–72 71can be used in emergency situations. Both vaccines can be admin-
istered by spray or drinking water e.g. in the regions around the
outbreak-centre, where poultry is still antibody negative for AIV.
Furthermore, a fast adaptation of the chimeric vaccine virus is
possible by substitution of the HPAIV H5 gene by the HA of cur-
rent circulating HPAIV, which can be followed by a save and fast
production of high virus amounts in ECE.
In the light of worldwide ND outbreaks every year, it is impor-
tant that ND vaccination is not impaired by any HPAIV vaccina-
tion strategy. Our chNDVFHNPMV8H5 chimeric vector vaccine in
conjunction with NDV vaccination fulﬁls this criterion by mediat-
ing protection against HPAIV H5N1 as well as ND. Another ap-
proach using bivalent killed vaccine mediated good protection
against both diseases but has the disadvantage requiring needle
vaccination [24]. In contrast to such vaccines, chNDVFHNPMV8H5
as well as rNDVGu are mass applicable. Furthermore, they are
well tolerated, regardless of the age of the chickens and
chNDVFHNPMV8H5 carries no risk of reassortment with circulat-
ing HPAIV because it lacks AIV-signal sequences.Conclusion
Vaccination with chNDVFHNPMV8H5 overcomes maternally
derived NDV immunity, a key property of poultry in NDV ende-
mic regions or countries practicing compulsory vaccination
against NDV. However, absence of NDV antigens HN and F results
in lack of protection against NDV in offspring of chNDVFHNPMV8-
H5 vaccinated chickens. To overcome this problem a vaccination
protocol was developed which includes a primary vaccination
with chNDVFHNPMV8H5 followed by vaccination against ND. This
approach would enable vaccination against HPAIV on day one in
the hatchery possibly by mass application via spray or drinking
water and would facilitate early onset of anti-AIV immunity. Fur-
thermore, chNDVFHNPMV8H5 carries the feature of a DIVA vac-
cine, important for AIV.
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